



NAVANA PHARMACEUTICALS LIMITED

Corporate Office : House # 99, Road #04, Block # B,
Banani, Dhaka-1213

PRICE SENSITIVE INFORMATION

This is for kind information to all valued shareholders of Navana Pharmaceuticals Limited and stakeholders that the Board of Directors of the company in its 21st meeting held on 24th January, 2023 ended at 4.00 p.m. has considered and approved, among others, the Un-audited Financial Statements for the Second quarter (Q2) period ended on December 31, 2022 and took the following Price Sensitive Decision:-

Comparative Statement on Un-audited Financial Statement for the Second quarter (Q2, FY-2022-2023) period ended on December 31, 2022:

Sl. No	Particulars	01.07.2022-31.12.2022	01.07.2021-31.12.2021	01.10.2022-31.12.2022	01.10.2021-31.12.2021
I	Net Profit After Tax	143,556,922	123,835,685	70,926,497	62,460,831
II	Weighted Average Number of Shares	91,642,306	80,230,150	91,642,306	80,230,150
III	Earnings Per Share (EPS)	1.57	1.54	0.77	0.78
IV	Net Operating Cash Flow Per Share(NOCFPS)	0.87	0.59	N/A	N/A
		As on 31.12.2022	As On 30.06.2022		
V	Net Asset Value (NAV)	4,249,685,678	3,483,049,324	N/A	N/A
VI	Net Asset Value Per Share	39.56	43.41	N/A	N/A

★ In compliance with the Dhaka & Chittagong Stock Exchange (Listing) Regulation, 2015, the company is pleased to publish the Un-audited Financial Statement for the Second quarter (Q2) period ended on December 31, 2022 in two widely circulated daily newspapers (one in Bengali and other one in English) and also in an online news portal. The detail of the published quarterly Financial Statements will be available in the website (www.navanapharma.com) of the company.

Dated: January 24, 2023

By order of the Board

Sd/-

Joynul Abedin ACS
Company Secretary